Scientists ‘must play in top league’

A Star chief says funding changes due to shifts in strategy amid worry over jobs, institute fate

A Star said it is funding changes due to shifts in strategy amid worry over jobs, institute fate

Simone Lim

The answer to the question of who has left the institute is not clearly stated in the text. It seems to be referring to the institute leaving the field or a particular person leaving the institute. The text mentions that there will be an incredible success, and they will have to keep up or brace for change. It also talks about having a new release and being very careful, which might indicate a transition or change in the institute's funding or strategy.

The model allows pharmaceutical companies to create a treatment platform for a disease. The text also mentions that successful innovations will be for competitive funding, and they are moving. These are steps it has taken to make the sector more agile and flexible in the use of funding.

The sector at a glance

- $650m: What Tessa Therapeutics raised
- $3.17m: What Invitrocue raised in a reverse takeover

Institute

A*Star scientists and run their own commercial drug discovery treatment for tuberculosis. The institute’s research extends its reach to new areas like biotech and consumer care.

BRIGHT SPARKS

Tessa Therapeutics

Singapore-based biotechnology company Tessa Therapeutics has announced a $650 million reverse takeover by a U.S. pharma firm. The company is developing a viral vector platform for personalized immunotherapy for cancer.

Invitrocue

Invitrocue, a Singapore-based biotechnology company, has announced a $3.17 million reverse takeover by a U.S. pharma firm. The company is developing a viral vector platform for personalized immunotherapy for cancer.

Commentary

Anxiety over funding, targets as research landscape evolves

Anxiety over funding, targets as research landscape evolves

Chung Ai-Liong

“Anxiety over funding, targets as research landscape evolves”

A Star chief Loo Chye Lin says the institute plans to be competitive in the field of biomedical research. He discusses the need for more agility and flexibility in the use of funds and mentions the importance of successful innovations.

The latest examples are the Singapore Institute of Molecular and Cell Biology, which targets blood cancers, and the Singapore National University of Technology and Design (SUTD), which targets skin and consumer care.

The firm is also currently conducting a genome-wide association study (GWAS) on type 2 diabetes. The study aims to identify genetic variants that contribute to the development of the disease.

The latest examples are the Singapore Institute of Molecular and Cell Biology, which targets blood cancers, and the Singapore National University of Technology and Design (SUTD), which targets skin and consumer care.

The firm is also currently conducting a genome-wide association study (GWAS) on type 2 diabetes. The study aims to identify genetic variants that contribute to the development of the disease.

The model allows pharmaceutical companies to create a treatment platform for a disease. The text also mentions that successful innovations will be for competitive funding, and they are moving. These are steps it has taken to make the sector more agile and flexible in the use of funding.

The sector at a glance

- $650m: What Tessa Therapeutics raised
- $3.17m: What Invitrocue raised in a reverse takeover

Institute

A*Star scientists and run their own commercial drug discovery treatment for tuberculosis. The institute’s research extends its reach to new areas like biotech and consumer care.

BRIGHT SPARKS

Tessa Therapeutics

Singapore-based biotechnology company Tessa Therapeutics has announced a $650 million reverse takeover by a U.S. pharma firm. The company is developing a viral vector platform for personalized immunotherapy for cancer.

Invitrocue

Invitrocue, a Singapore-based biotechnology company, has announced a $3.17 million reverse takeover by a U.S. pharma firm. The company is developing a viral vector platform for personalized immunotherapy for cancer.

Commentary

Anxiety over funding, targets as research landscape evolves

Anxiety over funding, targets as research landscape evolves

Chung Ai-Liong

“Anxiety over funding, targets as research landscape evolves”

A Star chief Loo Chye Lin says the institute plans to be competitive in the field of biomedical research. He discusses the need for more agility and flexibility in the use of funds and mentions the importance of successful innovations.

The latest examples are the Singapore Institute of Molecular and Cell Biology, which targets blood cancers, and the Singapore National University of Technology and Design (SUTD), which targets skin and consumer care.

The firm is also currently conducting a genome-wide association study (GWAS) on type 2 diabetes. The study aims to identify genetic variants that contribute to the development of the disease.

The latest examples are the Singapore Institute of Molecular and Cell Biology, which targets blood cancers, and the Singapore National University of Technology and Design (SUTD), which targets skin and consumer care.

The firm is also currently conducting a genome-wide association study (GWAS) on type 2 diabetes. The study aims to identify genetic variants that contribute to the development of the disease.

The model allows pharmaceutical companies to create a treatment platform for a disease. The text also mentions that successful innovations will be for competitive funding, and they are moving. These are steps it has taken to make the sector more agile and flexible in the use of funding.

The sector at a glance

- $650m: What Tessa Therapeutics raised
- $3.17m: What Invitrocue raised in a reverse takeover

Institute

A*Star scientists and run their own commercial drug discovery treatment for tuberculosis. The institute’s research extends its reach to new areas like biotech and consumer care.

BRIGHT SPARKS

Tessa Therapeutics

Singapore-based biotechnology company Tessa Therapeutics has announced a $650 million reverse takeover by a U.S. pharma firm. The company is developing a viral vector platform for personalized immunotherapy for cancer.

Invitrocue

Invitrocue, a Singapore-based biotechnology company, has announced a $3.17 million reverse takeover by a U.S. pharma firm. The company is developing a viral vector platform for personalized immunotherapy for cancer.

Commentary

Anxiety over funding, targets as research landscape evolves

Anxiety over funding, targets as research landscape evolves

Chung Ai-Liong

“Anxiety over funding, targets as research landscape evolves”

A Star chief Loo Chye Lin says the institute plans to be competitive in the field of biomedical research. He discusses the need for more agility and flexibility in the use of funds and mentions the importance of successful innovations.